The ability of existing questionnaires to measure symptom change after paracentesis for symptomatic ascites

Annals of Surgical Oncology

Volumn 14, Issue 8, 2007, Pages 2348-2357

  Easson, Alexandra M ^a   Bezjak, Andrea ^b   Ross, Susan ^c   Wright, Jim G ^d  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Ascites; Measurement; Palliation; Responsiveness; Symptom control

Indexed keywords

ADULT; ANOREXIA; ARTICLE; ASCITES; BLOATING; DIGESTIVE SYSTEM CANCER; DYSPNEA; EDMONTON SYMPTOM ASSESSMENT SCALE SHORT FORM; EUROPEAN ORGANIZATION FOR THE RESEARCH AND TREATMENT OF CANCER CORE QUALITY OF LIFE QUESTIONNAIRE; FATIGUE; FEMALE; FOLLOW UP; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; OVARY CANCER; PANCREATIC CANCER MODULE; PARACENTESIS; PATIENT MOBILITY; QUESTIONNAIRE; RELIABILITY; SENSITIVITY ANALYSIS; VALIDITY;

ASCITES; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; OVARIAN NEOPLASMS; PARACENTESIS; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SICKNESS IMPACT PROFILE;

EID: 34547474982     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-007-9370-3     Document Type: Article

References (35)

1. Easson AM, Lee KF, Brasel K, Krouse RS. Clinical research for surgeons in palliative care: challenges and opportunities. J Am Coll Surg 2003;196:141-51
2. Aaronson N, Alonso J, Burnam A. Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res 2002;11:193-205
3. Parsons SL, Lang MW, Steele RJC. Malignant ascites: a 2-year review from a teaching hospital. Eur J Surg Oncol 1996;22:237-9
4. Mackey JR, Venner PM. Malignant ascites: demographics, therapeutic efficacy and predictors of survival. Can J Oncol 1996;6:474-80
5. Gotlieb WH, Feldman B, Feldman-Moran O, et al. Intraperitoneal pressures and clinical parameters of total paracentesis for palliation of symptomatic ascites in ovarian cancer. Gynecol Oncol 1998;71:381-5
6. Hager ED, Dziambor H, Hohmann D, Muhe N, Strama H. Intraperitoneal hyperthermic perfusion chemotherapy of patients with chemotherapy-resistant peritoneal disseminated ovarian cancer. Int J Gynecol Cancer 2001;11(Suppl 1):57-63
7. Hirte HW, Miller D, Tonkin K, et al. A randomized trial of paracentesis plus intraperitoneal tumor necrosis factor-alpha versus paracentesis alone in patients with symptomatic ascites from recurrent ovarian carcinoma. Gynecol Oncol 1997;64:80-87
8. Sartori S, Nielsen I, Tassinari D, Trevisani L, Abbasciano V, Malacarne P. Evaluation of a standardized protocol of intracavitary recombinant interferon alpha-2b in the palliative treatment of malignant peritoneal effusions. A prospective pilot study. Oncology 2001;61:192-6
9. Ott MG, Mannel DN, Gallati H, Goerig M, Raeth U. Peripheral natural killer cell activity and intraperitoneal soluble p55 tumor necrosis factor receptor in patients with malignant ascites: two possible indicators for response to intraperitoneal combined tumor necrosis factor alpha and interferon gamma treatment. Cancer Immunol Immunother 1996;42:31-7
10. Lissoni P, Mandala M, Curigliano G, et al. Progress report on the palliative therapy of 100 patients with neoplastic effusions by intracavitary low-dose interleukin-2. Oncology 2001;60:308-12
11. Mackey JR, Wood L, Nabholtz J, Jensen J, Venner P. A phase II trial of triamcinolone hexacetanide for symptomatic recurrent malignant ascites. J Pain Symptom Manage 2000;19:193-9
12. McNamara P. Paracentesis-an effective method of symptom control in the palliative care setting? Palliat Med 2000;14:62-4
13. Edmonton Palliative Care Program. Edmonton Symptom Assessment System. 2002 http//www.palliative.org/PC/ClinicalInfo/AssessmentTools/esas.pdf
14. Chang VT, Hwang SS, Feuerman M. Validation of the Edmonton Symptom Assessment Scale. Cancer 2000;88:2164-71
15. Philip J, Smith WB, Craft P, Likiss N. Concurrent validity of the modified Edmonton Symptom Assessment System with the Rotterdam Symptom Checklist and the Brief Pain Inventory. Support Care Cancer 1998;6:539-41
16. Chang VT, Hwang SS, Feuerman M, Kasimis BS, Thaler HT. The memorial symptom assessment scale short form (MSAS-SF). Cancer 2000;89:1162-71
17. Portenoy RK, Thaler HT, Kornblith AB, et al. The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer 1994;30A:1326-36
18. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76
19. Bjordal K, de Graeff A, Fayers PM, et al. A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. EORTC Quality of Life Group. Eur J Cancer 2000;36:1796-807
20. Osoba D, Zee B, Pater J, Warr D, Kaizer L, Latreille J. Psychometric properties and responsiveness of the EORTC Quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res 1994;3:353-64
21. Fitzsimmons D, Johnson CD, George S, et al. Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC Study Group on Quality of Life. Eur J Cancer 1999;35:939-41
22. Pater J, Osoba D, Zee B, et al. Effects of altering the time of administration and the time frame of quality of life assessments in clinical trials: an example using the EORTC QLQ-C30 in a large anti-emetic trial. Qual Life Res 1998;7:273-8
23. Bruera E, Kuehn N, Miller MJ, Selmser P, MacMillan K. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 1991;7:6-9
24. Fayers PM, Aaronson NK, Bjordal K, et al. The EORTC QLQ-C30 Scoring Manual. 3rd ed. Brussels: European Organization for Research and Treatment of Cancer; 2001
25. O'Connor R. Measuring Quality of Life in Health. Philadelphia: Churchill Livingstone, 2004
26. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998;16:139-44
27. Kyriaki M, Eleni T, Efi P, Ourania K, Vassilios S, Lambros V. The EORTC Core Quality of Life Questionnaire (QLQ-C30, version 3.0) in terminally ill cancer patients under palliative care: validity and reliability in a Hellenic sample. Int J Cancer 2001;94:135-9
28. Feinstein AR. The theory and evaluation of sensibility. In: Clinimetrics. New Haven: Yale University Press, 1987:141-65
29. Hjermstad MJ, Fossa SD, Bjordal K, Kaasa S. Test/retest study of the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire. J Clin Oncol 1995;13:1249-54
30. Stromgren AS, Groenvold M, Pedersen L, Olsen AK, Sjogren P. Symptomatology of cancer patients in palliative care: content validation of self-assessment questionnaires against medical records. Eur J Cancer 2002;38:788-94
31. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 1994;47:81-7
32. Cohen J. Statistical Power Analysis for the Behavioral Sciences. New York: Lawrence Erlbaum, 1988
33. Beaton DE, Bombardier C, Hogg-Johnson SA. Measuring health in injured workers: a cross-sectional comparison of five generic health status instruments in workers with musculoskeletal injuries. Am J Ind Med 1996;29:618-31
34. Husted JA, Cook RJ, Farewell VT, Gladman DD. Methods for assessing responsiveness: a critical review and recommendations. J Clin Epidemiol 2000;53:459-68
35. Wright JG, Young NL. A comparison of different indices of responsiveness. J Clin Epidemiol 1997;50:239-46